The Evolution of Clinical Trials in Metastatic Breast Cancer: Design Features and Endpoints That Matter - on demand - the patient perspective @itsnot_pink and Tiah Tomlin @MyStyleMatters2 #ASCO20 1/5
Clinical trial features-Communication of medical research and clinical trials-clear/concise/visual. Patients as #partnersinresearch - share results. #MetastaticBC is a marathon - MTD may not be #TheRightDose. Reduce barriers - we need trials BECAUSE we are sick. #bcsm #ASCO20 2/5
Endpoints that matter? ASK the patient! All pts are different, and their answers may change over time. Living longer is always better, but progression free survival can have positives for patients-psychologically and possible keep symptoms from getting worse #bcsm #ASCO20 3/5
Quality of Life Matters to patients w/ #metastaticBC. Patients make trade-offs of length of time and quality of life, this is complex for each patient. Getting side effect info directly from other patients (PROs) is important. Measure what matters to patients. #bcsm #ASCO20 4/5
Quality of Life Matters to patients w/ #metastaticBC. Patients make trade-offs of length of time and quality of life, this is complex for each patient. Getting side effect info directly from other patients (PROs) is important. Measure what matters to patients. #bcsm #ASCO20 4/5
Quality of Life Matters to patients w/ #metastaticBC. Patients make trade-offs of length of time and quality of life, this is complex for each patient. Getting side effect info directly from other patients (PROs) is important. Measure what matters to patients. #bcsm #ASCO20 4/5
Diversity of participants in clinical trials is important. Lack of diversity can impact pts by not looking at side effects in different ethnic groups-possibly approving drugs successful in one subset of pts and ineffective/intolerable in a diff subset of pts. #bcsm #ASCO20 5/5
Diversity of participants in clinical trials is important. Lack of diversity can impact pts by not looking at side effects in different ethnic groups-possibly approving drugs successful in one subset of pts and ineffective/intolerable in a diff subset of pts. #bcsm #ASCO20 5/5
Diversity of participants in clinical trials is important. Lack of diversity can impact pts by not looking at side effects in different ethnic groups-possibly approving drugs successful in one subset of pts and ineffective/intolerable in a diff subset of pts. #bcsm #ASCO20 5/5
You can follow @paspears88.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.